HNGE vs USPH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HNGE is the larger of the two ($8.61B market cap): the incumbent the market prices for continued execution (32.53x forward earnings). USPH is the smaller challenger ($1.43B), priced similarly on forward earnings (28.55x): more room to run, but more to prove. HNGE is expected to grow revenue faster (27% vs 8% next year) at a similar price (32.53x vs 28.55x forward earnings). The case for USPH rests on its own driver (Hospital affiliations): if you believe in that, USPH fits; if you believe in what the numbers show today, HNGE does.

HNGE vs USPH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHNGEUSPHWhat it tells you
Market cap$8.61B$1.43BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E32.5328.55Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range79% of range87% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book28.723.34How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how HNGE and USPH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and USPH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and USPH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Hinge Health (HNGE) do?

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

What does U.S. Physical Therapy (USPH) do?

U.S. Physical Therapy, Inc. runs outpatient physical and occupational therapy clinics across the United States, about 799 locations at September 30, 2026, and an industrial injury prevention (IIP) business that sends athletic trainers and ergonomic specialists into employer worksites. Physical therapy produced about $190 million of Q3 2026 revenue and IIP about $33 million. The company's model is unusual: it buys a majority stake in a local practice, often 50% to 70%, and the founding therapists keep the rest and keep running it. That keeps clinicians invested, but it also means a large slice of profit belongs to partners, and the value of their stakes runs through earnings per share.

Full USPH guide

HNGE vs USPH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
  • USPH drivers: Hospital affiliations; Visit volume and rate per visit.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. For USPH, reimbursement is the largest outside risk.

HNGE or USPH: which should you pick?

If the story you believe is HNGE's (Employer benefit penetration), HNGE is the more direct way to own it; if it is USPH's (Hospital affiliations), USPH is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and USPH guides.

HNGE vs USPH: the full fundamentals

HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 29x trailing and 33x forward earnings and 11x sales after a ~132% year-to-date gain, the shares sit below the ~$135 average target of 16 analysts, and the forward multiple is higher than the trailing one because consensus 2027 EPS of about $3.26 is below a trailing figure lifted by one-time items. Fourth-quarter consensus is ~$0.73 of EPS on ~$249 million of revenue.

USPH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GAAP earnings are not a useful guide here, because the rising value of partners' stakes is charged against EPS without touching cash, which is why the company and analysts lean on adjusted EPS and EBITDA. Even on those measures the stock is not cheap after rising about 17% in three sessions after the report and holding most of that gain. Published analyst targets moved up after the quarter, with Barrington at $122, and the mean of about $111.50 across six analysts sits roughly 16% above the November 20 close.

Headline figures (approximate, November 2026): HNGE shows revenue (ttm) ~$801 million; Q3 2026 ~$235.0 million, up ~52% year over year, gross / operating margin ~86% / ~19%, net income (ttm) ~$166 million (Q3 2026 ~$57.4 million), adjusted eps (q3 2026) ~$0.71 vs ~$0.60 estimate; USPH shows revenue (ttm) ~$838 million (Q3 2026 ~$223 million, up ~13% year over year), adjusted ebitda (ttm) ~$100 million (2026 guidance $102 million to $106 million), eps (ttm) Adjusted ~$2.68 (Q3 $0.80); GAAP ~-$1.34 after partner-stake revaluation, valuation ~36x trailing adjusted EPS; ~17x to ~20x trailing adjusted EBITDA; ~29x 2027 consensus EPS of ~$3.37.

The bottom line: HNGE vs USPH

HNGE and USPH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined HNGE and USPH exposure against your real portfolio. It is not an investment adviser.

Wondering how HNGE or USPH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Hinge Health

Ask Walnut's AI anything about HNGE and see how it fits what you own.

FAQ

What is the difference between HNGE and USPH?

+

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. U.S. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HNGE or USPH the better stock?

+

Neither is universally better. HNGE is the larger incumbent; USPH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HNGE or USPH?

+

On forward P/E (as of November 2026), HNGE trades at 32.53x and USPH at 28.55x, so USPH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HNGE and USPH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HNGE vs USPH?

+

HNGE: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Valuation is now the most visible risk: after a ~133% one-year gain the stock trades around 29x trailing earnings, 33x forward earnings, 11x sales and 29x book value as of November 2026, so a revenue deceleration or another small EPS miss like Q2 2026 (~$0.59 versus ~$0.62 expected) could move the shares sharply; the stock already fell about 16% from its 52-week high of ~$126, set after mid-October. Recent IPO dynamics persist, with continuing insider sales, including a ~$20.6 million sale disclosed in October 2026 and a ~$4.4 million sale disclosed in November, adding supply and shaping sentiment. USPH: Reimbursement is the largest outside risk. Medicare cut therapy rates for several years before 2026, and part of the 2026 increase came from a one-year boost set by Congress, so a cut in the 2027 fee schedule would hit revenue per visit directly. Commercial insurers can also push rates down or tighten visit limits. Labor is the second: physical therapists are in short supply, wages keep rising, and the company's self-insured health plan has been running well above last year's costs. The partnership structure adds complexity. Partners hold about $357 million of redeemable stakes that USPH may have to buy back under put rights, and their rising value has pushed GAAP EPS negative in three of the last four quarters (a $1.04 loss in Q3) even as adjusted earnings grew. The hospital affiliations are concentrated, with 60 of the 72 clinics tied to one New York system, and the company lists termination of an affiliation as a risk. Weather and seasonality move results, as the 31,000 lost visits in Q1 showed. The CFO seat turned over this year, with Nchacha Etta (formerly of Omnicell) starting September 1. Finally, after the jump to about $99.50 and a close near $96 on November 20, 2026, the stock trades within about 15% of the mean analyst target of roughly $111.50, so the cushion between price and published expectations is thin.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HNGE or USPH; figures are approximate and dated (as of November 2026). Verify current data before investing.